Shots: The P-III ASCEND study results involve assessing of Calquence as monothx. (100mg, bid) vs Rituximab + Idelalisib (IdR) or Bendamustine (BR) in 310 patients in a ratio (1:1) with […]readmore
Tags : ASCEND
Shots: The P-III ASCEND study involves assessing of Calquence (acalabrutinib, 100mg, q2d) vs Rituximab + Idelalisib/Bendamustine in 310 previously treated patients in a ratio (1:1) with CLL The P-III ASCEND […]readmore